Literature DB >> 7593452

Cellular localization of the growth hormone receptor/binding protein in the human anterior pituitary gland.

H C Mertani1, C Pechoux, T Garcia-Caballero, M J Waters, G Morel.   

Abstract

The increasing use of GH therapy has led to the description of its target cells in human tissues, but no data are yet available on the localization of the GH receptor in the human pituitary. In the present study, we used immunocytochemistry to detect the presence of GH receptor/binding protein (GHR/BP), and we examined its distribution among the different types of human anterior pituitary cells. Human pituitaries were taken from autopsies and were processed for embedding in paraffin wax. Immunocytochemistry was performed by using monoclonal antibody 263 raised against purified rat and rabbit GHR/BP, which cross-reacts with the human GH receptor. In order to determine the types of cells that display immunoreactivity for GHR/BP, adjacent pituitary sections were used to detect immunoreactivity for GH, PRL, ACTH, TSH, LH, and FSH. Several controls were carried out to verify the specificity of the immunostaining. Receptor immunoreactivity was found in the cytoplasm and nuclei of the somatotrophs, lactotrophs, and gonadotrophs but not in the thyrotrophs or corticotrophs. In order to demonstrate that the detected GHR/BP immunoreactivity was not caused solely by a cellular capture, we also investigated the cellular distribution of GHR gene expression. This was performed by in situ hybridization with use of complementary oligonucleotide radioactive probes encoding distinct domains of the GHR. Several tests were carried out to validate the detection of gene expression. In situ hybridization demonstrated the presence of GHR messenger RNAs in the anterior lobe of human pituitary, and examination of the signal strengthened the cell-specificity of GHR gene expression. These results demonstrate the presence of GHR/BP in discrete human pituitary cells and indicate a paracrine, autocrine, or intracrine role for GH in the pituitary.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593452     DOI: 10.1210/jcem.80.11.7593452

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Gene Expression in Mouse Thyrotrope Adenoma: Transcription Elongation Factor Stimulates Proliferation.

Authors:  Peter Gergics; Helen C Christian; Monica S Choo; Adnan Ajmal; Sally A Camper
Journal:  Endocrinology       Date:  2016-07-19       Impact factor: 4.736

Review 2.  Hypothalamic and hypophyseal regulation of growth hormone secretion.

Authors:  M T Bluet-Pajot; J Epelbaum; D Gourdji; C Hammond; C Kordon
Journal:  Cell Mol Neurobiol       Date:  1998-02       Impact factor: 5.046

3.  Characterization of c-kit (CD117) expression in human normal pituitary cells and pituitary adenomas.

Authors:  Stefano La Rosa; Silvia Uccella; Linda Dainese; Silvia Marchet; Claudia Placidi; Davide Vigetti; Carlo Capella
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

4.  Growth hormone/STAT5 signaling in proopiomelanocortin neurons regulates glucoprivic hyperphagia.

Authors:  Paula G F Quaresma; Pryscila D S Teixeira; Isadora C Furigo; Frederick Wasinski; Gisele C Couto; Renata Frazão; Edward O List; John J Kopchick; Jose Donato
Journal:  Mol Cell Endocrinol       Date:  2019-09-05       Impact factor: 4.102

5.  Increased expression of growth hormone and prolactin receptors in hepatocellular carcinomas.

Authors:  T García-Caballero; H M Mertani; A Lambert; R Gallego; M Fraga; E Pintos; J Forteza; M Chevallier; P E Lobie; B K Vonderhaar; A Beiras; G Morel
Journal:  Endocrine       Date:  2000-06       Impact factor: 3.925

6.  In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells.

Authors:  Thomas Cuny; Caroline Zeiller; Martin Bidlingmaier; Céline Défilles; Catherine Roche; Marie-Pierre Blanchard; Marily Theodoropoulou; Thomas Graillon; Morgane Pertuit; Dominique Figarella-Branger; Alain Enjalbert; Thierry Brue; Anne Barlier
Journal:  Endocr Relat Cancer       Date:  2016-06-07       Impact factor: 5.678

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.